Massachusetts’s General Hospital Study Demonstrates Prevencio’s AI-driven HART CVE Blood Test Highly Accurate

AI-driven, multiple protein blood test data presented at 2022 American Heart Association Scientific Sessions

Prevencio, announces the presentation of patient data demonstrating its Artificial Intelligence (AI)-driven HART CVE blood test is highly accurate in determining whether a person with chronic kidney disease (CKD) will have a heart attack or major adverse cardiac event within the next two years. Presented at this week’s American Heart Association (AHA) Scientific Sessions, the HART CVE blood test data significantly improves risk classification of patients with CKD, thereby allowing for more personalized therapy across cardiac risk categories.

Browse The Complete News About Blockchain : Blockchain Partnership: PraSaga and Metahug Gamify Web3 Education Via Roblox

“This HART CVE application is valuable for both hospitalized and outpatient chronic kidney patients. We are highly grateful for our collaboration with Massachusetts General Hospital and look forward to assisting in the advanced cardiac healthcare for the 37 million U.S. CKD patients.”

Researchers from Massachusetts General Hospital tested 446 CKD patients undergoing coronary or peripheral angiography to predict two-year risk of heart attack, stroke, or cardiovascular death. When the HART CVE result was divided into low-risk and high-risk categories, the test showed a highly accurate Hazard Ratio (HR) of 8.32, meaning that a CKD patient with a high-risk score had more than 8 times the risk for a major adverse cardiac event within two years as compared to a CKD patient with a low-risk score.

“It is impressive this test provides robust accuracy among patients at different stages of CKD,” said James L. Januzzi, MD, a practicing cardiologist at Massachusetts General Hospital, Professor of Medicine at Harvard Medical School and Principal Investigator in development, validation, and ongoing testing of the HART CVE test. “This accuracy across the different stages is important given a sharp increase in cardiovascular event risk as patients progressively decline in kidney function. With the rapid rise in CKD, better tools to recognize risk and intervene proactively are needed. Our data suggest that this AI-derived, multi-protein, algorithmically scored risk test may be useful to individualize cardiac risk assessment and foster aggressive primary and secondary cardiovascular prevention.”

Next-gen AI-On-Demand Platform :  European Commission Pumps in $9.15 Million to Develop Next-gen AI-On-Demand Platform

Kidney disease is a public health epidemic affecting more than 850 million people globally. The Centers for Disease Control and Prevention estimates that 15% of U.S. adults, or more than 37 million people, have CKD. As many as 9 in 10 adults with CKD, and 2 in 5 adults with severe CKD do not know they have the condition as it can be largely asymptomatic. CKD is an expensive disease, accounting for 20% of total Medicare expenditures, which is more than $120 billion annually. CKD patients incur medical expenditures which are almost three times as much as non-CKD patients.

“Prevencio is committed to providing clinicians with safer, highly accurate, and more affordable ways to identify and treat the tens of millions of patients at risk for adverse cardiac events,” said Rhonda Rhyne, President and Chief Executive Officer of Prevencio. “This HART CVE application is valuable for both hospitalized and outpatient chronic kidney patients. We are highly grateful for our collaboration with Massachusetts General Hospital and look forward to assisting in the advanced cardiac healthcare for the 37 million U.S. CKD patients.”

In addition to the HART CVE test for risk of major cardiac events, Prevencio offers a second multi-protein blood test, HART CADhs, for diagnosing obstruction of the heart arteries. HART CADhs was shown to be more accurate (86% AUC accuracy) than standard-of-care stress tests (52% AUC accuracy). HART CVE and HART CADhs tests are currently available to medical professionals for patient use